NCT02481882

Brief Summary

This study will provide information on cortical haemodynamics in MS patients to address the discrepancies reported in previous literature, allowing further insight into the role of haemodynamics in the disease. It will also instruct us as to the most effective scanning protocols for future research. Developing a suitable protocol for studying perfusion longitudinally may also enable identification of new therapeutic interventions to normalise any perfusion abnormalities in MS patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P75+ for not_applicable multiple-sclerosis

Timeline
Completed

Started Jan 2017

Typical duration for not_applicable multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 19, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 25, 2015

Completed
1.5 years until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2019

Completed
Last Updated

October 12, 2018

Status Verified

October 1, 2018

Enrollment Period

2.7 years

First QC Date

May 19, 2015

Last Update Submit

October 11, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cerebral Blood Flow

    A short MRI scan is able to quantify the amount of blood perfusion into brain tissue (to be performed with and without the gadolinium contrast agent).

    1 hour

Secondary Outcomes (2)

  • Arterial Cerebral Blood Volume

    1 hour

  • Arterial Transit Time

    1 hour

Study Arms (2)

Healthy Volunteers

OTHER

Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.

Device: Magnetic Resonance Imaging

MS Patients

OTHER

Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).

Device: Magnetic Resonance ImagingDrug: Prohance (Gadoteridol)

Interventions

All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.

Healthy VolunteersMS Patients

A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.

MS Patients

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female volunteers who are between the ages of 21 and 80.
  • Able to give voluntary written informed consent to participate in the study.
  • Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures.
  • Diagnosed with Multiple Sclerosis.
  • Male or female volunteers who are between the ages of 21 and 80.
  • Able to give voluntary written informed consent to participate in the study.
  • Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures.

You may not qualify if:

  • Any history of neurological illness other than MS.
  • Known hypersensitivity to any MR or X-Ray contrast agent.
  • Any history of renal failure or disease.
  • Any history of allergies.
  • Any history of circulation problems (vascular disease).
  • Pregnancy or breastfeeding.
  • MRI contraindications as screened on safety questionnaire (e.g. metal implants or pacemaker).
  • Have taken part in any other clinical study within the previous 3 months.#
  • Any contraindications provided from MRI or contrast agent safety forms.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Queen's Medical Centre

Nottingham, Nottinghamshire, NG7 2RD, United Kingdom

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis

Interventions

Magnetic Resonance Imaginggadoteridol

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

TomographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Nikos Evangelou, Ph.D.

    Faculty of Medicine & Health Sciences

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 19, 2015

First Posted

June 25, 2015

Study Start

January 1, 2017

Primary Completion

October 1, 2019

Study Completion

October 1, 2019

Last Updated

October 12, 2018

Record last verified: 2018-10

Data Sharing

IPD Sharing
Will not share

Locations